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to, (b) the result of hard quantitative data on the other side. If we use
the perfect consensus model, then we are back to where evidence-
based medicine (EBM) started twenty years ago. EBM proponents then
demanded that clinical experts should step down as review authors
because of their notoriously unsystematic evaluations of the literature. In
this perspective, a high level of consensus may rather be a measure of
the opinions among stakeholders, than synonymous with best evidence.
On the other hand, we still struggle with the handling of quantitative data
to make trustworthy comparisons across interventions.
A systematic review of non-steroidal anti-inﬂammatory drugs (NSAID)
in knee osteoarthritis which we performed, can serve as an example
of the difﬁculties associated with quantitative data. We found that some
trials only recruited known responders to NSAID who had 49.4% higher
effect size compared to patients in trials which did not. The inﬂated
effect size in the subgroup of biased trials, led to an overall inﬂated
effect size by 24.3%. This fact hampers valid comparisons between
NSAID and other interventions. Because of the strict exclusion of co-
interventions in most NSAID-trials, there is also a lack of data for the effect
of NSAID in combination with potentially effective exercise therapy. There
are examples of trials with other interventions which do the opposite,
and recruit known non-responders in addition to allowing effective co-
interventions. Comparisons across interventions may then be ﬂawed.
Conclusions: There is still a way to go before we can be satisﬁed with
our methods for synthesizing best evidence. When a consensus-oriented
approach is selected, it seems important to balance guidelines developer
groups with involved stakeholders. If best evidence is sought from hard
quantitative data, more attention should probably be paid to differences
in patient selection criteria, intervention characteristics and allowed co-
interventions.
I-4 RESOURCES FOR FUTURE GUIDELINES & RESEARCH:
AN OARSI ‘TOOLBOX’ AND AN ‘EVIDENCE-BASED OA
RESEARCH DATABASE’ (EBOARD)
W. Zhang1, G. Nuki2. 1Nottingham University, Nottingham, UNITED
KINGDOM, 2University of Edinburgh, Edinburgh, UNITED KINGDOM
Purpose: More than 50 pharmacological, non-pharmacological and sur-
gical therapies are available for treating osteoarthritis (OA) [1] and
there are now 25 published guidelines for the management of OA.
The Osteoarthritis Research Society International (OARSI) has recently
published 25 recommendations for the management of hip and knee
OA [2]. However guidance for patients and clinicians on the order in which
such treatments, or combination of treatments, should be offered is much
less secure. While algorithms are frequently promulgated as simple aids
to guide physicians and patients through the welter of options, evidence
to support the use of one treatment prior to another is rarely available,
The clinical application of algorithms is also restricted by the need to tailor
treatment to the individual patient depending on the severity of symptoms,
the stage of disease, the presence of comorbidities, the risk of side effects
and the use of other drugs, etc.
An alternative approach which OARSI is developing is a toolbox con-
taining all effective treatment options. This is more ﬂexible to apply and
in many instances better supported by research evidence. It also has
the advantage that decisions to use one and/or another recommended
treatment is made by the users themselves, rather than by the guideline
developers.
The relevance and utility of treatment guidelines is also time limited by
the rapid accumulation of new research evidence. Risk-beneﬁt ratios for
some therapies currently recommended by OARSI have already changed
and some of the differences in the recommendations for the treatment of
OA contained in the NICE guidelines published in February 2008 [3] are
attributable to such new research evidence. So which guidelines should
one follow and how should one assess and weight the quality of evidence?
While one can criticise the OARSI guidelines for pooling results from all
RCTs regardless of quality, one must also be aware of potential bias
when different quality criteria are used for determining recommendations
for different modalities of therapy. It is, however, impossible to apply the
same quality criteria to all modalities of therapy unless all individual trials
are collected and characterised.
We therefore propose to develop an Evidence based OA Research
Database (eBOARD). This will be a comprehensive and coherent
database of well characterised trials of all modalities of treatment for
OA. In addition to containing details of patient demographics, disease
characteristics and treatments it will include quality assessments using
a single, standard instrument and measures of outcomes such as ES,
NNT, RR/OR and cost/QALY. The database will be updated annually with
the key messages and summary statistics for each therapy. We believe
that this database will be useful for (1) developing and updating treat-
ment guidelines; (2) answering speciﬁc clinical questions concerning the
efﬁcacy or side effects of any modality of therapy; undertaking evidence
based research, such as meta-analysis, sensitivity analysis, and cumula-
tive meta-analysis. It will also provide an unconstrained hypothesis-free
database of OA therapy that can be used to generate and test new
hypotheses.
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I-5 MOVING FROM GUIDELINES TO STANDARDS OF CARE
C. Kwoh. University of Pittsburgh, Pittsburgh, PA, USA
Purpose: Treatment guidelines are designed to assist clinical decision-
making by deﬁning a set of optimal patient care strategies. The best
treatment guidelines are evidence-based, but there are often limitations
in the availability of data from clinical trials to inform their development.
Guidelines are therefore frequently a combination of expert opinion and
the best available evidence.
What are the next steps after the development of treatment guidelines?
Ideally, guidelines also identify gaps in knowledge and areas where more
evidence would be helpful. Guidelines need to be disseminated to the
target audience of providers. Effective dissemination often requires a
multi-pronged approach.
The ultimate goal of treatment guidelines is to improve the quality of
care for a given condition through improved patient outcomes, enhanced
physician efﬁciency and/or greater health system productivity. Quality
indicators or performance standards are designed to deﬁne a minimally
acceptable level of care. Quality indicators may address a combination of
overuse, underuse or misuse of diagnostic and/or treatment modalities.
Quality indicators should be relevant, have scientiﬁc validity and be
feasible for implementation into clinical practice.
Methods: Quality indicators are used to assess the quality of care
delivered by providers, hospitals, health systems and/or other health care
organizations. Benchmarking can be used to summarize the performance
of a speciﬁc group of entities on a set of quality indicators to identify the
highest and lowest performing entities. Quality indicators can also be
used to identify/deﬁne/recognize the highest quality providers or health
systems. Risk adjustment may be needed to control for differences in
case-mix among providers or health systems.
Quality improvement is based on measurement. A performance measure
is a set of technical speciﬁcations that deﬁne how to calculate a “rate” for
a particular quality indicator. This rate is equivalent to the numerator, or
number of eligible patients who meet the quality indicator divided by the
denominator, or number of patients who meet inclusion criteria minus the
number of patients excluded due to medical, patient, or health system
reasons.
Results: The development of quality indicators is similar to the process
of developing treatment guidelines. A priority area is identiﬁed; a panel
of experts is convened; the available evidence is summarized through
a literature review; a draft set of measures is deﬁned; the expert panel
evaluates the draft set of measures; speciﬁcations are developed to deﬁne
the numerator of eligible patients who meet the quality indicator, the
denominator of patients who meet inclusion criteria, and potential reasons
for excluding patients from the denominator. The performance measure
undergoes ﬁeld-testing to assess feasibility.
Conclusions: Existing examples of quality indicators for knee and hip
osteoarthritis will be presented.
I-6 RISK STRATIFICATION FOR OA PROGRESSION
D.J. Hunter. New England Baptist Hospital, Boston, MA, USA
Purpose: The medial compartment of the knee is the most common site
of involvement in knee OA, and has been the subject of the most previous
studies in this context. Although many joint structures are affected in
OA, OA manifests prominently in the articular cartilage. Traditionally the
progression of knee OA has been assessed by measuring changes in
the width of the space between the medial femoral condyle and medial
tibial plateau on plain x-rays. More recently interest has grown in the
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application of direct measurements of change in cartilage on MRI. The
design of MRI-based efﬁcacy studies includes decisions on sample size,
based on estimations of statistical power derived from prior data or
expectations concerning progression. The sample size depends on (a) the
expected rate of progression in participants treated with placebo, (b) the
minimum size of drug effect judged to be clinically relevant, or rate of
progression expected in the active treatment arm(s), (c) the variation in
progression rate that occurs between participants, and (d) the precision of
the measurement technique. Despite results from older studies in persons
with knee OA suggesting rates of change for cartilage volume loss in
the range of 5−7% per year, more recent studies including from the
OAI have produced more conservative estimates in the range of 1−3%
per year with substantive variability. To date despite major advances
in measurement methods, structure-modifying efﬁcacy has not been
convincingly demonstrated for any of the existing pharmacologic agents.
Current trials have wanted for more responsive outcome measures both
for symptoms and structure in order to identify change.
Methods: Thus conservative study designs based on large x-ray and MRI
progression series currently in the public domain require large sample
sizes. If we could conﬁdently design studies based on smaller sample
sizes and/or shorter study durations, this would reduce the resource
implications for MRI based interventional studies.
Results: An increase in the study power could be gained by selecting
participants that have features that predict rapid progression in future
studies. Several studies have suggested that baseline clinical, biomarker
and imaging features are predictive of more rapid progression of cartilage
loss in the medial compartment of the knee. These include increased
body mass index (BMI), an increased level of type II collagen C-terminal
degradation products detected in the urine, the presence of varus mal-
alignment at the tibiofemoral joint, the presence on MRI of subchondral
bone marrow lesions or meniscal abnormalities.
Conclusions: These studies that stratify risk of OA progression will be
discussed along with their implications for screening failure rates in clinical
trials.
I-7 PLACEBO RESPONSE IN OA TRIALS
M. Doherty. University of Nottingham, Nottingham, UNITED KINGDOM
Purpose: Clinical evidence of non-speciﬁc treatment effects, often termed
“placebo effect”, has been documented in a wide range of conditions.
Such non-speciﬁc beneﬁts could result from a patient’s response to
observation and assessment (Hawthorne effect), the administration of
a therapeutic treatment or ritual (placebo treatment), or the patient-
practitioner interaction. Randomised controlled trials (RCTs) to investigate
the beneﬁts of a treatment attempt to take into account such non-speciﬁc
effects by use of a placebo control. However, some investigators have
questioned whether the placebo effect exists at all, preferring to explain
improvements from baseline on placebo in terms of natural disease
remission or chance regression to the mean. Recently we undertook a
systematic review and meta-analysis of RCTs in OA to determine whether
there is evidence for placebo effects in OA and to examine potential
determinants of the size of such effects.
Methods: A systematic literature search was undertaken using Medline,
EMBASE, Scientiﬁc Citation Index, CINAHL and Cochrane Library. Ran-
domised placebo controlled trials in OA were included. The placebo effect
was estimated as the effect size (ES) – the standard mean difference
between baseline and endpoint. This was compared with the ES obtained
from untreated (observation) controls. ES for pain was the primary
outcome. Statistical pooling was undertaken as appropriate and 95%
conﬁdence interval (CI) was used for comparison. Quality of trials was
assessed and potential determinants of placebo effect were examined
using multiple regression analysis. Partial regression coefﬁcient (b) was
used to present the adjusted size of the association.
Results: We identiﬁed 198 trials with 193 placebo groups (16,364 pa-
tients) and 14 untreated control groups (1,167 patients) that met our inclu-
sion criteria. These included a range of therapies (non-pharmacological,
pharmacological and surgical treatments). The following results were
obtained:
1. Placebo was effective at relieving pain (ES=0.51, 95%CI 0.46, 0.55).
This effect was superior to untreated control (ES=0.03, 95%CI −0.13,
0.18), supporting placebo as a real entity.
2. Placebo also improved function (ES=0.49, 95%CI 0.44, 0.54) and
stiffness (ES=0.43, 95%CI 0.38, 0.49), but the highest ES was
for physician global assessment (ES=0.66, 95%CI 0.53, 0.78). No
improvements were seen for more objective measures such as quadri-
ceps strength, knee circumference or range of movement.
3. Placebo ES for pain relief was higher with treatments that had a
larger effect, perhaps reﬂecting greater expectancy of efﬁcacy from
the patient.
4. Placebo ES increased as baseline pain and sample size increased.
5. Route of delivery affected placebo ES for pain, with highest effects
seen when given by injection (higher with multiple than single injec-
tions), needling, and topical application.
6. Placebo ES for pain was highest for hand OA (0.80, 95%CI 0.65,
0.96), intermediate for knee OA (0.54, 95%CI 0.49, 0.6) and lowest
for hip OA (0.37, 95%CI 0.21, 0.53) perhaps implying that hip OA is
more severe disease and less amenable to non-speciﬁc effects.
Conclusions: Although regarded largely as a “nuisance” in RCTs, it is
apparent that non-speciﬁc effects of treatment in OA confer greater beneﬁt
in terms of symptom improvement than the effect derived from the more
speciﬁc effect of any one treatment. This has clear implications for design
of RCTs. More importantly, however, it emphasises the potential major
role for non-treatment effects in the medical care of people with OA and
should encourage us to investigate ways of optimising such beneﬁts.
I-8 OARSI-OMERACT SET OF CRITERIA IN KNEE/HIP
OSTEOARTHRITIS TO BE USED AS A HARD ENDPOINT
IN CLINICAL TRIALS EVALUATING POTENTIAL
DISEASE-MODIFYING DRUGS
L. Gossec. Cochin Hospital, Paris Descartes University, Paris, FRANCE
Purpose: Little is known about the natural course of deterioration of pain,
physical function or joint structure as a result of hip or knee osteoarthri-
tis. An international OARSI/OMERACT working group was created; the
objectives are to develop pain, physical function and structure states
that represent the progression from early to late disease for individuals
with OA of the hip and knee. These states are planned to be used as
a “hard endpoint” in potential disease-modifying drug trials, with some
states deﬁning “heoretical need for total joint replacement”.
Methods: New questionnaires were created to assess pain and functional
impairment. Structural assessments have been compared and structural
severity was deﬁned as joint space width loss on radiographs. A large
multicenter study is ongoing to assess these criteria.
Results:Work is ongoing. Current results will be presented at the OARSI
meeting.
Conclusions: The ﬁnal objective will be to combine the 3 domains (pain,
function and structure) and to create a composite index to deﬁne states
of severity and “theoretical need for total joint replacement” in hip/knee
osteoarthritis.
I-9 TRADEOFFS BETWEEN PAIN RELIEF AND THE RISK OF
SIDE EFFECTS IN THE TREATMENT OF OA: THE PATIENT’S
PERSPECTIVE
J. Kopec1, C.G. Richardson1, H. Llewellyn-Thomas2, A. Klinkhoff1,
A. Carswell3, A. Chalmers1. 1University of British Columbia, Vancouver,
BC, CANADA, 2Dartmouth Medical School, Hanover, NH, USA,
3Dalhousie University, Halifax, NS, CANADA
Purpose: Therapeutic decisions in osteoarthritis (OA) often involve trade-
offs between accepting risks of side effects and gaining pain relief.
Previous studies suggested that the risk of side effects affected treat-
ment preferences but data on patients’ preferences for speciﬁc trade-offs
between pain relief and each side effect of treatment in OA are scarce.
Our objectives were (1) to determine patients’ maximum acceptable risk
increments (MARI) for different adverse effects from OA medication and
(2) to identify the predictors of these preferences.
Methods: Participants were individuals diagnosed with OA of the hip
or knee according to standard ACR criteria, age 45−74, able to under-
stand English and mentally competent. They were stratiﬁed into three
categories of disease severity – mild, moderate, and severe. MARI were
measured with a probabilistic threshold technique (TT). Risk and pain
levels in the TT scenarios were controlled for in a 2×2 randomized facto-
rial design. Clinical, sociodemographic, and psychological characteristics
(decisional conﬂict and locus of control) of the participants were assessed
using a self-administered questionnaire.
Results: 196 subjects participated in the study. For most side effects,
higher initial-risk levels in the TT tasks were associated with subjects’
reports that they would be willing to accept higher additional risks.
Depending on the initial level of risk and pain relief, mean MARI ranged
from 3% to 5% for heart attack/stroke, 5% to 8% for stomach bleed, 13%
to 21% for hypertension, 22% to 33% for ﬂuid retention, and 23% to 35%
